Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factor and treatment strategy for clinical N1 non-small cell lung cancer

  • Original Article
  • Published:
General Thoracic and Cardiovascular Surgery Aims and scope Submit manuscript

Abstract

Objectives

The aim of this study is to evaluate the surgical results of clinical N1 disease and to clarify the high-risk clinical N1 subgroup.

Methods

Between 1990 and 2012, 137 patients who were clinically diagnosed as having N1 disease were enrolled. Their medical records were reviewed to assess clinical characteristics, radiologic findings, pathologic results, postoperative outcomes, recurrence patterns, and survival. Logistic regression analysis was used to identify independent predictive factors for pathologic N2 upstaging. To determine which factors were significantly associated with survival, a multivariate analysis using a Cox proportional hazards model was performed.

Results

More cases were pathological N2 in adenocarcinoma than squamous cell carcinoma (p = 0.039). The overall survival rates at 5 years were 54.9%, 36.7% in group upper lobe, middle and lower lobe, respectively (p = 0.013). Logistic regression analyses revealed that #10 positive (p = 0.002, HR 4.625) and adenocarcinoma (p = 0.029, HR 1.544) were significant predictor of pathologic N2 disease. Multivariate analyses revealed that pathologic N2 (p = 0.007, HR 4.186), middle and lower lobe (p = 0.009, HR 2.045) and presence of #10 (p = 0.024, HR 1.871) were independent prognostic factors. Patients with upper lobe and absence of #10 showed a significantly higher 5-year survival rate than patients with middle and lower lobe and presence of #10 (62.1 vs 25.9%: p < 0.0001).

Conclusions

Among patients with cN1, pathological N2 disease, tumor in middle and lower lobe and clinical #10 lymph node positive were high-risk subgroup. Further analyses using larger numbers of patients with N1 disease from multiple centers are necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer. Ann Thorac Surg. 2005;79:1682–6.

    Article  Google Scholar 

  2. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.

    Article  CAS  Google Scholar 

  3. Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M, For the International Staging Committee, Cancer Research, and Biostatistics, Observers to the Committee, Participating Institutions, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM classification for the lung cancer. J Thorac Oncol. 2007;2:603–12.

    Article  Google Scholar 

  4. Shin S, Kim HK, Choi YS, Kim K, Kim J, Shim YM. Prognosis of unexpected and expected pathologic N1 non- small cell lung cancer. Ann Thorac Surg. 2013;96(3):969–75.

    Article  Google Scholar 

  5. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:202S–20S.

    Article  Google Scholar 

  6. Choi YS, Shim YM, Kim J, Kim K. Mediastinoscopy in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2003;75:364–6.

    Article  Google Scholar 

  7. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Weder W, et al. Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines. Transl Lung Cancer Res. 2014;3(4):225–33.

    PubMed  PubMed Central  Google Scholar 

  8. Ernst A, Eberhardt R, Krasnik M, Herth FJ. Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration of hilar lymph nodes for diagnosing and staging cancer. J Thorac Oncol. 2009;4:947–50.

    Article  Google Scholar 

  9. Decaluwe H, Dooms C, De Leyn P, Thomas P, Rami-Porta R. Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease. Eur Respir J. 2018;51(4):1800410. https://doi.org/10.1183/13993003.00410-2018.

    Article  PubMed  Google Scholar 

  10. Libshitz HI, McKenna RJ Jr. Mediastinal lymph node size in lung cancer. AJR. 1984;143:715–8.

    Article  CAS  Google Scholar 

  11. Gross BH, Glazer GM, Orringer MB, Spizarny DL, Flint A. Bronchogenic carcinoma metastasis to normal-sized lymph nodes: frequency and significance. Radiology. 1988;166:71–4.

    Article  CAS  Google Scholar 

  12. Hishida T, Yoshida J, Nishimura M, Nishiwaki Y, Nagai K. Problems in the current diagnostic standards of clinical N1 non-small cell lung cancer. Thorax. 2008;63:526–31.

    Article  CAS  Google Scholar 

  13. Miyoshi K, Mimura T, Iwanaga K, Adachi S, Tsubota N, Okada M. Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis. Surg Today. 2010;40:428–32.

    Article  Google Scholar 

  14. Fukui T, Kato K, Okasaka T, Kawaguchi K, Fukumoto K, Yokoi K, et al. Predictors for hilar/intrapulmonary lymph node metastasis in discrete type of clinical N1 non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2017;65:640–5.

    Article  Google Scholar 

  15. van Velzen E, Snijder RJ, Brutel de la Riviere A, Elbers HR, van den Bosch JM. Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg. 1997;63:1436–40.

    Article  Google Scholar 

  16. Tanaka F, Yanagihara K, Otake Y, Yamada T, Shoji T, Wada H, et al. Prognostic factors in patients with resected pathologic T1–2N1M0 non-small cell lung cancer. Eur J Cardiothorac Surg. 2001;19:555–61.

    Article  CAS  Google Scholar 

  17. Riquet M, Manach D, Le Pimpec-Barthes F, Dujon A, Chehab A. Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg. 1999;67:1572–6.

    Article  CAS  Google Scholar 

  18. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Stephens R, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet. 2007;369:1929–37.

    Article  CAS  Google Scholar 

  19. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–71.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic, Cardiovascular and General Surgery, Kanazawa University, Takara-machi 13-1, Kanazawa, 920-8640, Japan

    Masaya Tamura, Isao Matsumoto, Yusuke Tanaka, Daisuke Saito, Shuhei Yoshida, Munehisa Takata & Hirofumi Takemura

Authors
  1. Masaya Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isao Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuke Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daisuke Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuhei Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Munehisa Takata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirofumi Takemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaya Tamura.

Ethics declarations

Conflict of interest

The authors declare no competing financial interests associated with this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tamura, M., Matsumoto, I., Tanaka, Y. et al. Prognostic factor and treatment strategy for clinical N1 non-small cell lung cancer. Gen Thorac Cardiovasc Surg 68, 261–265 (2020). https://doi.org/10.1007/s11748-019-01205-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-019-01205-4

Keywords

Search

Navigation